Total Revenue
Neurocrine Biosciences Total Revenue increased by 1.1% to $814.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.2%, from $572.60M to $814.50M. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 26.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $288.90M | $296.00M | $312.00M | $310.60M | $378.20M | $387.90M | $412.00M | $420.40M | $452.70M | $498.80M | $515.20M | $515.30M | $590.20M | $622.10M | $627.70M | $572.60M | $687.50M | $794.90M | $805.50M | $814.50M |
| QoQ Change | — | +2.5% | +5.4% | -0.4% | +21.8% | +2.6% | +6.2% | +2.0% | +7.7% | +10.2% | +3.3% | +0.0% | +14.5% | +5.4% | +0.9% | -8.8% | +20.1% | +15.6% | +1.3% | +1.1% |
| YoY Change | — | — | — | — | +30.9% | +31.0% | +32.1% | +35.4% | +19.7% | +28.6% | +25.0% | +22.6% | +30.4% | +24.7% | +21.8% | +11.1% | +16.5% | +27.8% | +28.3% | +42.2% |
Product Breakdown — Net product sales
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Collaboration revenues | $6.40M | $5.50M | $6.50M | $8.90M | $5.50M | $5.00M | $7.20M | $3.50M |
| Total | $590.20M | $622.10M | $627.70M | $572.60M | $687.50M | $794.90M | $805.50M | $814.50M |
Product Breakdown — INGREZZA
| Segment | FY'22 | FY'23 |
|---|---|---|
| INGREZZA | $1.40B | $1.80B |
| Total | $1.49B | $1.89B |
All segment values are derived from annual filings.
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $572.60M | $687.50M | $794.90M | $805.50M | $814.50M |
| Total | $572.60M | $687.50M | $794.90M | $805.50M | $814.50M |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's total revenue?
- Neurocrine Biosciences (NBIX) reported total revenue of $814.50M in Q1 2026.
- How has Neurocrine Biosciences's total revenue changed year-over-year?
- Neurocrine Biosciences's total revenue increased by 42.2% year-over-year, from $572.60M to $814.50M.
- What is the long-term trend for Neurocrine Biosciences's total revenue?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's total revenue has grown at a 26.0% compound annual growth rate (CAGR), from $1.13B to $2.86B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.